We designed Sigyn Therapy to overcome the limitations of previous drug and device candidates to address acute inflammatory disorders, including sepsis, the leading cause of hospital deaths.
Our CompanyA critical care treatment opportunity reported to exceed $20 billion.
Sigyn Therapy is a patent-pending blood purification technology to mitigate Cytokine Storm Syndrome through the broad-spectrum depletion of life-threatening inflammatory targets from the entire bloodstream.
About Sigyn TherapyPrior to their creation of Sigyn Therapy, our co-founders played instrumental roles in the development of three different technologies that the United States Food and Drug Administration (FDA) has permitted for use to treat COVID-19 infected individuals.
